FLC Capital Advisors Purchases 5,556 Shares of Pfizer Inc. (NYSE:PFE)

FLC Capital Advisors lifted its holdings in Pfizer Inc. (NYSE:PFE) by 16.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,772 shares of the biopharmaceutical company’s stock after acquiring an additional 5,556 shares during the quarter. FLC Capital Advisors’ holdings in Pfizer were worth $1,122,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Los Angeles Capital Management LLC increased its position in Pfizer by 59.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 47,663 shares of the biopharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 17,799 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Pfizer by 9.1% during the 1st quarter. GAMMA Investing LLC now owns 13,768 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 1,149 shares in the last quarter. Signal Advisors Wealth LLC bought a new position in Pfizer in the 1st quarter valued at $232,000. Bruce G. Allen Investments LLC increased its stake in shares of Pfizer by 13.2% in the 1st quarter. Bruce G. Allen Investments LLC now owns 6,942 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 811 shares during the period. Finally, Banque Cantonale Vaudoise raised its position in shares of Pfizer by 95.5% during the first quarter. Banque Cantonale Vaudoise now owns 469,711 shares of the biopharmaceutical company’s stock worth $13,036,000 after acquiring an additional 229,471 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.10.

Pfizer Stock Up 0.7 %

Shares of Pfizer stock opened at $29.66 on Thursday. The company has a market capitalization of $168.07 billion, a P/E ratio of -494.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a 50-day moving average of $29.04 and a two-hundred day moving average of $28.42. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $33.19.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.66%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.